Acta Pharmaceutica Sinica B

Acta Pharmaceutica Sinica B

Volume 11, Issue 8, August 2021, Pages 2096-2113
Acta Pharmaceutica Sinica B

REVIEW
Cell membrane-derived vesicles for delivery of therapeutic agents

https://doi.org/10.1016/j.apsb.2021.01.020Get rights and content
Under a Creative Commons license
open access

Abstract

Cell membranes have recently emerged as a new source of materials for molecular delivery systems. Cell membranes have been extruded or sonicated to make nanoscale vesicles. Unlike synthetic lipid or polymeric nanoparticles, cell membrane-derived vesicles have a unique multicomponent feature, comprising lipids, proteins, and carbohydrates. Because cell membrane-derived vesicles contain the intrinsic functionalities and signaling networks of their parent cells, they can overcome various obstacles encountered in vivo. Moreover, the different natural combinations of membranes from various cell sources expand the range of cell membrane-derived vesicles, creating an entirely new category of drug-delivery systems. Cell membrane-derived vesicles can carry therapeutic agents within their interior or can coat the surfaces of drug-loaded core nanoparticles. Cell membranes typically come from single cell sources, including red blood cells, platelets, immune cells, stem cells, and cancer cells. However, recent studies have reported hybrid sources from two different types of cells. This review will summarize approaches for manufacturing cell membrane-derived vesicles and treatment applications of various types of cell membrane-derived drug-delivery systems, and discuss challenges and future directions.

Graphical abstract

Cell membrane-derived nanovesicles contain the intrinsic functionalities of their parent cells, and have potential as new molecular delivery systems.

Image 1
  1. Download : Download high-res image (256KB)
  2. Download : Download full-size image

KEY WORDS

Cell membrane-derived vesicles
Membrane engineering
Drug-delivery systems
Blood cells
Immune cells
Stem cells
Cancer cells
Manufacturing

Abbreviations

CAR-T
chimeric antigen receptor-engineered T cell
CRISPR
clustered regularly interspaced short palindromic repeats
CXCR4
C-X-C chemokine receptor type 4
DC
dendritic cell
NF-κB
nuclear factor kappa B
NIR
near infrared
PEG
polyethylene glycol
PLGA
poly(lactic-co-glycolic acid)
RBC
red blood cell
TCR
T-cell receptor
TRAIL
tumor necrosis factor-related apoptosis-inducing ligand

Cited by (0)

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

These authors made equal contributions to this work.